ZAPI GROUP Showcases New Solutions in Material Automation at LogiMAT 2024
19.3.2024 16:00:00 EET | Business Wire | Press release
ZAPI GROUP, a global leader in electrification, announced today it is showcasing its solutions for the material handling and electrification industries at LogiMAT 2024. At the event, ZAPI GROUP is announcing the expansion of BlueBotics, a ZAPI GROUP company and leader in autonomous navigation technology. BlueBotics has partnered with Pramac, a leading global supplier of warehouse material handling equipment, and expanded its ANT server mission and fleet management software. These milestones bolster ZAPI GROUP's standing as a comprehensive autonomous navigation and AGV fleet management provider for electrification.
"The expansion of BlueBotics is an exciting milestone as ZAPI GROUP continues to grow its capabilities to serve the global AGV and material handling sectors," noted Lloyd Gomm, Global Marketing Director at ZAPI GROUP. "BlueBotics’ consistent innovation in navigation software enables the company to broaden the spectrum of solutions and integrated systems available to our OEM customers. LogiMAT presents an opportunity to showcase these developments and other product innovations with the industry.”
The ZAPI GROUP is exhibiting at LogiMAT 2024 in Stuttgart from March 19 - 21 in hall 6, booth 6C61. They provide a wide array of capabilities for OEMs with a range of electrification and automation solutions for material handling machines and robots, including inverters and controllers, electric motors, high-frequency battery chargers and accessories. Its companies leading innovation across AGV and material handling sectors include BlueBotics, Zapi, Inmotion Technologies, Delta-Q Technologies, Zivan, Schabmüller, 4E Consulting, Best Motor and ZTP.
At the ZAPI GROUP booth at LogiMAT, the BlueBotics team is announcing the agility of its ANT server fleet management software to control not only more than 100 “ANT driven” customer vehicles but also now VDA 5050-compliant AGVs and AMRs. The company will also demo Pramac’s X-ACT HYBRIX robot, a new line of X-ACT mobile logistics robots powered by BlueBotics’ latest version of its software, as part of its on-stand multi-brand AGV/AMR fleet demo.
“We are thrilled to further expand our suite of autonomous navigation and AGV fleet management solutions,” said BlueBotics’ CEO, Dr. Nicola Tomatis. “BlueBotics has a proven track record of developing autonomous solutions for a variety of mobile robotic platforms. These solutions continue to complement ZAPI GROUP's existing system integration capabilities, advance its electrification mission and enhance OEMs’ access to robust solutions for material handling automation.”
The ZAPI GROUP recently hosted industry leaders at its annual virtual conference, The Future of Electrification. This was the company’s third year hosting the event aimed to drive education and innovations for electrification across its key industries.
To learn more about ZAPI GROUP and its companies, visit them at LogiMAT 2024 (hall 6, stand 6C61).
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, high-frequency battery chargers, and autonomous navigation software for application in full-electric and hybrid vehicles. As a global electrification leader with deep systems experience, leading innovations, and an obsession with driving customers' success, ZAPI GROUP now counts more than 1700 employees worldwide with total annual revenue of more than 700 million US dollars.
For more information about the group, visit www.zapigroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319748003/en/
Contact information
AnnMarie Carson, Communiqué PR
Phone: (206) 282-4923 ext. 119
Email: zapigrouppr@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom